Springer Nature
Browse
13024_2022_561_MOESM3_ESM.tif (3.73 MB)

Additional file 3 of Farnesyltransferase inhibitor LNK-754 attenuates axonal dystrophy and reduces amyloid pathology in mice

Download (3.73 MB)
figure
posted on 2022-08-21, 03:11 authored by Leah K. Cuddy, Alia O. Alia, Miranda A. Salvo, Sidhanth Chandra, Tom N. Grammatopoulos, Craig J. Justman, Peter T. Lansbury, Joseph R. Mazzulli, Robert Vassar
Additional file 3: Supplementary Fig. 3. LNK-754 reduces amyloid burden and tau pathology in female and male 5XFAD mice. A Immunoblot of brain homogenates from vehicle, LNK-754 and lonafarnib treated 5XFAD mice probed for APP (6E10) and actin. Quantification of APP (B) in male (C) and female (D) mice. E Immunoblot of brain homogenates from male vehicle, LNK-754 and lonafarnib treated 5XFAD mice probed for phospho-tau (P-tau ser404) and total tau (Tau1). Quantification of phospho-tau (P-tau ser404) normalized to total tau in male and female (immunoblots shown in Fig. 1H) mice (*p = 0.012) (F). Vehicle, n = 11 (5 males, 6 females); LNK-754, n = 10 (4 males, 6 females); lonafarnib n = 10 (4 males, 6 females). Triangles represent males and circles represent females. 1-way ANOVA with Tukey’s post-hoc multiple comparisons test and 2-way ANOVA were performed.

Funding

National Institutes of Health

History

Usage metrics

    Molecular Neurodegeneration

    Exports

    RefWorks
    BibTeX
    Ref. manager
    Endnote
    DataCite
    NLM
    DC